ImmPORT Therapeutics Inc. dba Antigen Discovery Inc (ADi) is nominated for Tibbetts Award because it exemplifies what SBIR program is designed for. ADi has received multiple SBIR/STTR awards in past 7 years from the NIH and the National Institute of Allergy and Infectious Diseases (NIAID). With the help of these grants, and a worldwide exclusive license of the core technology from the University of California, ADi has quickly become a recognized leader in the field of antigen/biomarker discovery by using its proprietary high throughput proteomics platform technology to translate readily available genomic information into development of next generation diagnostics, vaccines and therapeutics. In addition to more than 70 scientific publications, 4 issued US patents and several pending patent applications, ADi has been awarded numerous R&D and co-development contracts from the US government, Bill & Melinda Gates Foundation, and other non-profit organizations like FIND Diagnostics, Seattle Biomedical Research Institute (SBRI), University of Texas Medical Branch (UTMB), etc as well as from private biotech/pharmaceutical companies worldwide. ADi is the sole commercial provider of full proteome microarrays for many important infectious disease targets such as Mycobacterium tuberculosis, malaria, Staphylococcus aureus, Borrelia burgdorferi (Lyme disease), etc. Antigen Discovery Inc. stands out among many biotech businesses in that it has been self sufficient since day one and has not yet needed any outside investment (e.g. venture capital or angel investors). The start-up fund came entirely from SBIR/STTR awards, near term revenue comes from commercializing ADi’s novel proteome microarray based biomarker/antigen screen system as bioscience products and services, and long term sustained growth will stem from diagnostic, vaccine and therapeutic products under development. Besides its symbiotic relationship with the University of California, company has established partnerships with the CDC, US Navy, Bill & Melinda Gates Foundation, the NIH/NIAID, and leading pharmaceutical/diagnostic companies. ADi is in the process of maturing from a start-up to a commercialization stage biotech company, anticipating validation and launch of world first robust and rapid serological test for active TB and a more accurate and simplified test for Lyme disease in the near future.